Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Flavin reductase (NADPH), commonly referred to as NADPH-methemoglobin reductase in clinical contexts, is a cytosolic enzyme primarily responsible for the reduction of flavins and biliverdin IX-beta [18, 21]. While it plays a minor role (less than 5%) in the physiological reduction of methemoglobin under normal conditions, it becomes the critical pathway for the pharmacological treatment of methemoglobinemia [1, 3, 7]. When the drug methylene blue is administered, this enzyme reduces it to leukomethylene blue using NADPH as an electron donor [8, 10]. Leukomethylene blue then acts as a potent electron carrier to non-enzymatically reduce ferric iron (Fe3+) in methemoglobin back to the functional ferrous state (Fe2+) in hemoglobin [9, 15]. This enzyme's activity is strictly dependent on the availability of NADPH, which is primarily generated by the pentose phosphate pathway; consequently, its therapeutic efficacy is compromised in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [10, 12]. Beyond its role in methemoglobinemia, the enzyme is involved in the reduction of biliverdin and various flavins, and it has been identified as a heme-binding protein in both erythrocytes and the liver [16, 21]. It also possesses protein nitrosyltransferase activity, contributing to the regulation of various signaling pathways [21]. The enzyme is distinct from the NADH-dependent cytochrome b5 reductase, which is the primary physiological system for methemoglobin maintenance [1, 19]. Therapeutic use of methylene blue targeting this enzyme requires careful monitoring due to risks of serotonin syndrome and interference with pulse oximetry readings [8, 25].
Methylene blue acts as an artificial electron carrier; the enzyme reduces methylene blue to leukomethylene blue using NADPH, and leukomethylene blue then non-enzymatically reduces methemoglobin to hemoglobin.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Flavin reductase (NADPH) (BLVRB) (BLVRB).